4 hours ago
1
Panama7/iStock Editorial via Getty Images
Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (VIGL) for $470M in cash, potentially reaching $600M with milestone payments.
Sanofi (NASDAQ:SNY) said it purchased Vigil (VIGL) for an upfront payment of $8/share, and Vigil
English (US) ·